Genetics  


Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria 
Condition: Phenylketonuria
Intervention: Drug: rAvPAL-PEG
Principal Investigator: Barbara K. Burton, M.D.
Phone: 773-880-4462
IRB Number: 2008-13453 (ClinicalTrials.gov identifier: NCT00634660)

The Fabrazyme┬« and Arbs and ACE Inhibitor Treatment (FAACET) Study 
Principal Investigator: Joel Charrow, MD
Contact: Shanna Randolph, APN
Phone: 773-880-4462
Email:
  
ClinicalTrials.gov identifier: NCT00446862

International Collaborative Gaucher Group (ICGG) Gaucher Registry 
Principal Investigator: Joel Charrow, MD
Phone: 773-880-4462
Email:
  
ClinicalTrials.gov Identifier: NCT00358943

Pompe Disease Registry 
Principal Investigator: Joel Charrow, MD
Phone: 773-880-4462
Email:
  
ClinicalTrials.gov Identifier: NCT00231400

Fabry Disease Registry 
Principal Investigator: Joel Charrow, MD
Phone: 773-880-4462
Email:

ClinicalTrials.gov identifier: NCT00196742

 Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
Principal Investigator: Joel Charrow, MD

Phone: 773-880-4462
Email:

ClinicalTrials.gov identifier: NCT00925301
 


Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU (PKU-015)
Principal Investigator: Barbara K. Burton, M.D.
Phone: 773-880-4462
Email:[email protected]
ClinicalTrials.gov identifier: NCT00838435  (CMMC IRB# 2009-137970)